Recent events
Recent events tied to this brand in public sources.
Back to profile1 entries
2021
NovaBiotics NM002 included in REMAP-CAP Phase 3 trial
NovaBiotics announced that its intravenous cysteamine bitartrate candidate NM002 was included in the global REMAP-CAP Phase 3 clinical trial for community acquired pneumonia. NovaBiotics provided doses for the initial UK phase and developed a manufacturing process to supply the rest of the trial.